Clinical trial

A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

NCT06025110

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention TCD601 Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2023-01-23

PhasePHASE2

Conditions

Diabetes Mellitus, Type 1unresolved

Interventions

TCD601BIOLOGICAL

PlaceboOTHER

Sponsors & collaborators

ITB-Med LLClead sponsor

Mapped research locations

BarcelonaSpain2 LondonUnited Kingdom2 MilanItaly2 SevilleSpain1 BrusselsBelgium1 LeuvenBelgium1 StockholmSweden1 BirminghamUnited Kingdom1 CambridgeUnited Kingdom1 OxfordUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06025110 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.